MODIFICATION
Q -- USDA COVID Testing
- Notice Date
- 2/14/2022 12:13:28 PM
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- FPAC BUS CNTR-ACQ DIV WASHINGTON DC 20250 USA
- ZIP Code
- 20250
- Solicitation Number
- 12FPC2-22-Q-0004
- Response Due
- 2/23/2022 10:00:00 AM
- Archive Date
- 03/10/2022
- Point of Contact
- Craig Harper
- E-Mail Address
-
craig.harper@usda.gov
(craig.harper@usda.gov)
- Small Business Set-Aside
- SBA Total Small Business Set-Aside (FAR 19.5)
- Description
- The United States Department of Agriculture is adopting a testing policy to safeguard the health and well-being of its employees, their families, and the communities we serve from COVID-19. In an effort to maintain a safe and healthy workplace and workforce, USDA plans to implement routine testing as an effective method of identifying and addressing the risk of COVID-19 transmission. USDA�s COVID screening testing program is anticipated to be used by a subset of USDA employees who perform work at a USDA worksite and/or routinely interact with the public.� The screening testing program will require employee testing at least once a week for every week the employee will interact with others in a work capacity, in-person.� Additional testing for employees may also be implemented to address unique testing needs for specific roles or functions unique to USDA, specific situations and/or for diagnostic testing when a workplace exposure occurs; this testing would not be routine, would be scheduled as needed and is estimated to account for 20% of USDA�s COVID testing need. USDA requires employees to be tested for SARS-CoV-2 primarily with rapid antigen tests, with nucleic acid amplification tests (NAAT) polymerase chain reaction (PCR) as a backup if supply of rapid antigen tests becomes limited.� All tests must be authorized by the Food and Drug Administration to detect current infection. Testing must adhere to current CDC COVID testing standards. USDA intends to acquire the commercial services of a testing provider, who shall have the capability to provide �at home� COVID-19 Rapid Antigen kits and NAAT PCR testing kits. Certified observers supplied by the testing provider will supervise the testing process virtually, confirming employee identity, overseeing proper sample collection, and authenticating results during a telehealth visit. A mechanism for employee scheduling and confirmation of recurring and ad-hoc COVID testing appointments shall be provided by the testing provider. Test results will be provided securely by the testing provider to the employee who was tested and to the agency.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/48631dd1e1c64e1fafafae35d6b64d09/view)
- Record
- SN06241339-F 20220216/220214230105 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |